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Objective: This screening study at 35-37 weeks’ gestation investigates the potential value of 
uterine artery pulsatility index (UtA-PI) and serum levels of the angiogenic placental growth 
factor (PlGF) and antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT-1) in the 
prediction of adverse perinatal outcome in small for gestational age (SGA) and non-SGA 
neonates.  
 
Methods: This was a prospective observational study in 19,209 singleton pregnancies 
attending for a routine hospital visit at 35+0 - 36+6 weeks’ gestation. This visit included 
recording of maternal demographic characteristics and medical history, sonographic 
estimation of fetal weight (EFW), color Doppler ultrasound for measurement of the mean 
UtA-PI, and measurement of serum concentration of PlGF and sFLT. Multivariable logistic 
regression analysis was carried out to determine which of the factors from maternal or 
pregnancy characteristics and measurements of UtA-PI, PlGF and sFLT-1, provided a 
significant contribution in the prediction of each of four adverse outcome measures: first, 
stillbirth, second, cesarean section for presumed fetal compromise in labor, third, neonatal 
death or hypoxic ischemic encephalopathy grades 2 and 3, and fourth, admission to the 
neonatal unit (NNU) for ≥48 hours. Predicted probabilities from logistic regression analysis 
were used to construct receiver operating characteristic (ROC) curves to assess 
performance of screening for these adverse outcomes. 
 
Results: First, 83% of stillbirths, 82% of cesarean sections for presumed fetal compromise in 
labor, 91% of cases of neonatal death or hypoxic ischemic encephalopathy and 86% of NNU 
admissions for ≥48 hours occurred in pregnancies with non-SGA babies. Second, UtA-PI 
>95th percentile, sFLT-1 >95th percentile and PLGF <5th percentile were associated with 
increased risk of cesarean section for presumed fetal compromise in labor and NNU 
admission for ≥48 hours; the number of stillbirths and cases of neonatal death or hypoxic 
ischemic encephalopathy was too small to demonstrate significance in the observed 
differences from cases without these adverse outcomes. Third, multivariable regression 
analysis demonstrated that in prediction of cesarean section for presumed fetal compromise 
in labor there was no significant contribution from biomarkers; the prediction of NNU 
admission for ≥48 hours by maternal demographic characteristics and medical history was 
only marginally improved by the addition of UtA-PI, sFLT-1 or PlGF. Fourth, for each 
biomarker the detection rate of adverse outcomes was higher in SGA than in non-SGA 
neonates, but such increase was accompanied by an increase in false positive rate. Fifth, 
the relative risk of UtA-PI >95th, sFLT-1 >95th and PLGF <5th percentiles for most adverse 
outcomes was <2.5 in both SGA and non-SGA neonates. 
 
Conclusions: In pregnancies undergoing routine antenatal assessment at 35-37 weeks’ 
gestation measurements of UtA-PI, sFLT-1 or PlGF provide poor prediction of adverse 
perinatal outcome in both SGA and non-SGA fetuses.  
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INTRODUCTION 
 
Routine assessment of pregnancy at 35-37 weeks’ gestation is useful in the prediction of 
subsequent development of pre-eclampsia (PE) and the birth of a small-for gestational-age 
(SGA) neonates.1,2 Both conditions are associated with impaired placentation and/or 
placental dysfunction, reflected in increased pulsatility index (PI) in the uterine arteries 
(UtAs), reduced serum level of the angiogenic placental growth factor (PlGF) and increased 
level of the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT-1).1-6  
 
Small for gestational age fetuses / neonates are at increased risk of adverse perinatal 
outcome, including stillbirth, cesarean section for presumed fetal compromise and admission 
to the neonatal unit for ≥48 hours.7-10 However, >80% of adverse perinatal events at term 
occur in babies with birthweight ≥10th percentile.7-10 On the assumption that at least some of 
the adverse perinatal events in both SGA and non-SGA babies are a consequence of failure 
to reach a normal growth potential due to impaired placentation, it should be anticipated that 
high UtA-PI and sFLT-1 and low PlGF would be good predictors of adverse outcome.  
 
The objective of this screening study at 35-37 weeks’ gestation was to investigate the 
potential value of UtA-PI and serum levels of PlGF and sFLT-1 in the prediction of adverse 





Study design and participants 
 
This was a prospective study in women attending for a routine hospital visit at 35+0 - 36+6 
weeks’ gestation at King’s College Hospital, London or Medway Maritime Hospital, 
Gillingham, UK between between March 2014 and September 2018. This visit included 
recording of maternal demographic characteristics and medical history, ultrasound 
examination for fetal anatomy and measurement of fetal head circumference, abdominal 
circumference and femur length for calculation of estimated fetal weight (EFW) (using the 
formula by Hadlock et al,11 because a systematic review identified this as being the most 
accurate model12), transabdominal color Doppler ultrasound for measurement of the mean 
UtA-PI,13 and measurement of serum concentration of PlGF and sFLT in pg/mL by an 
automated biochemical analyzer (Cobas e411 system, Roche Diagnostics, Penzberg, 
Germany, or BRAHMS KRYPTOR compact PLUS, Thermo Fisher Scientific, Hennigsdorf, 
Germany). Gestational age was determined by the measurement of fetal crown-rump length 
at 11-13 weeks or the fetal head circumference at 19-24 weeks.14,15 The women gave written 
informed consent to participate in the study, which was approved by the NHS Research 
Ethics Committee. 
 
Inclusion / exclusion criteria 
 
The inclusion criteria for this study were singleton pregnancies examined at 35+0 - 36+6 
weeks’ gestation and delivering a non-malformed live birth or stillbirth. We excluded 
pregnancies with aneuploidies and major fetal abnormalities. Some of the patients in this 




Patient characteristics recorded included maternal age, racial origin (White, Black, South 
Asian, East Asian and mixed), method of conception (spontaneous or assisted by use of 
ovulation induction drugs or in vitro fertilization), cigarette smoking during pregnancy, 
medical history of chronic hypertension or diabetes mellitus, obstetric history (nulliparous if 
no previous pregnancies at ≥24 weeks and parous with or without previous history of 
delivery of SGA neonate with birthweight <10th percentile) and presence of PE, obstetric 
cholestasis or gestational diabetes mellitus in the current pregnancy. Maternal weight and 




Data on pregnancy outcome were collected from the hospital delivery records. The following 
outcome measures were considered: first, stillbirth, second, cesarean section for presumed 
fetal compromise in labor, third, neonatal death or hypoxic ischemic encephalopathy grades 
2 and 3, and fourth, admission to the neonatal unit (NNU) for ≥48 hours. Cesarean section 
for presumed fetal compromise in labor was carried out if there was evidence of a 
pathological electronic fetal heart rate pattern, abnormalities in ST waveform analysis of fetal 
electrocardiogram and / or abnormal fetal scalp blood pH.17,18 Hypoxic-ischemic 
encephalopathy was diagnosed when there was disturbed neurologic function with evidence 
of perinatal hypoxia reflected in either a 5-minute Apgar score <5 or umbilical artery cord pH 
<7.0 or base deficit >12 mmol/L, supported by neuroimaging evidence of acute brain injury. 
The definition of SGA fetus or neonate was based on EFW and birthweight, respectively, 
<10th percentile for gestational age based on the Fetal Medicine Foundation fetal and 




Categorical data are presented as n (%) and continuous data as median and interquartile 
range (IQR). Mann-Whitney U-test and χ2-square test or Fisher’s exact test, were used for 
comparing outcome groups for continuous and categorical data, respectively. Significance 
was assumed at 5%. 
Univariable and multivariable logistic regression analysis was carried out to determine which 
of the factors from maternal or pregnancy characteristics and measurements of UtA-PI, PlGF 
and sFLT-1, provided a significant contribution in the prediction of each of the four outcome 
measures. Prior to the regression analysis, the continuous variables, such as age, weight 
and height were centred by subtracting the arithmetic mean from each value. Multiple 
categorical variables were dummy coded as binary variables to estimate the independent 
effect of each category. The measured, PlGF, sFLT-1 and UtA-PI were converted to 
multiples of the median (MoM) after adjustment for variables from maternal characteristics 
and medical history that affect these measurements.1,20 The birth weight Z-score was 
derived from the Fetal Medicine Foundation fetal and neonatal population weight charts.19 
We estimated cut-offs for the 95th percentiles for UtA-PI and sFLT-1 and <5th percentile for 
PlGF and determined the prevalence of abnormal values in each of the outcome groups. 
The values of UtA-PI >95th percentile, sFLT-1 >95th percentile and PLGF <5th percentile 
were used as binary categorical variables in the multivariable regression analysis. Predicted 
probabilities from logistic regression analysis were used to construct receiver operating 
characteristic (ROC) curves to assess performance of screening for these adverse 
outcomes. We examined the detection rate (DR), false positive rate (FPR), relative risk and 
positive and negative likelihood ratios (LR) of UtA-PI >95th, sFLT-1 >95th and PLGF <5th 
percentiles for each adverse perinatal outcome in the sub-groups of SGA (birthweight <10th 
percentile) and non-SGA (birthweight ≥10th percentile) fetuses and neonates. 
The statistical package SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0, 







The characteristics of the study population of 19,209 singleton pregnancies, including 19,174 
with livebirths and 35 with stillbirths are summarized in Table 1. 
 
The 19,174 pregnancies with livebirths, included 14,170 with vaginal delivery following 
spontaneous or induced labor, 72 with elective cesarean section for suspected fetal 
compromise due to abnormal Doppler findings or fetal-heart rate patterns in SGA fetuses 
and 2,201 with elective cesarean section for a variety of other indications (breech or 
transverse lie, placenta previa, previous cesarean section or traumatic birth, maternal 
medical disorder or maternal request) and 2,731 with cesarean section following 
spontaneous or induced labor; in the latter group, the indication for cesarean section was 
presumed fetal compromise in 1,007 cases.  
 
In the livebirths there were 2 neonatal deaths and 30 cases with HIE grades 2 or 3 and 
1,323 cases of NNU admission for ≥48 hours (including the 30 cases of HIE). 
 




In stillbirths, compared to livebirths, there was a higher median sFLT-1 MoM and a higher 
incidence of UtA-PI and sFLT-1 >95th and BW <10th percentiles (Table 1). Multivariable 
regression analysis demonstrated that the only significant predictors of stillbirth were 
maternal BMI and parous women with a previous delivery of SGA neonate, but not from UtA-
PI >95th, sFLT-1 >95th, PLGF <5th or EFW <10th percentiles (R2=0.018; p=0.010; Table S1).  
 
Cesarean section for presumed fetal compromise in labor 
 
In those delivering by cesarean section for presumed fetal compromise in labor, compared to 
those with vaginal delivery, there was first, higher median maternal weight and body mass 
index, and higher incidence of women of Black racial origin, conception by in vitro 
fertilization, nulliparity, chronic hypertension, diabetes mellitus, PE and gestational diabetes; 
second, higher median sFLT-1 MoM; and third, higher incidence of  UtA-PI and sFLT-1 
>95th, PLGF <5th and birthweight <10th percentiles (Table 1).  
 
Multivariable regression analysis demonstrated that in prediction of cesarean section for 
presumed fetal compromise in labor there was a statistically significant contribution from 
maternal age, body mass index, smoking, Black and mixed racial origin, parity, chronic 
hypertension, diabetes mellitus and PE, but not from UtA-PI >95th, sFLT-1 >95th, PLGF <5th 
or EFW <10th percentiles (R2=0.101; p<0.001; Table S1). 
 
Neonatal death or hypoxic ischemic encephalopathy 
 
In those with neonatal death or hypoxic ischemic encephalopathy, compared to those 
without these adverse events, there was higher incidence of Black racial origin, parous 
women without previous SGA and PE. There was no significant difference in median UtA-PI 
MoM, sFLT-1 MoM, PLGF MoM and there was no significant difference in the incidence of  
UtA-PI >95th, sFLT-1 >95th, PLGF <5th or EFW <10th percentiles (Table 1).  
 
Multivariable regression analysis demonstrated that in prediction of neonatal death or 
hypoxic ischemic encephalopathy there was a statistically significant contribution from parity 
and PE, but not from UtA-PI >95th, sFLT-1 >95th, PLGF <5th or EFW <10th percentiles 
(R2=0.022; p=0.006; Table S1). 
 
Neonatal unit admission for ≥48 hours 
 
In those with NNU admission for ≥48 hours, compared to those without this adverse event, 
there was first, higher median body mass index and lower maternal age, higher incidence of 
smokers, White and South Asian racial origin, conception with use of ovulation induction 
drugs, diabetes mellitus, gestational diabetes, obstetric cholestasis and PE and lower 
incidence of parous women with or without previous SGA, second, higher median sFLT-1 
MoM and lower median PLGF MoM, and third, higher incidence of UtA-PI and sFLT-1 >95th, 
PLGF <5th, and birthweight <10th percentiles (Table 1).  
 
Multivariable regression analysis demonstrated that in prediction of NNU admission for ≥48 
hours there was a statistically significant contribution from maternal age, body mass index, 
Black and South Asian racial origin, parous women with or without previous SGA, obstetric 
cholestasis, PE, sFLT-1 >95th, PLGF <5th percentiles and estimated fetal weight <10th 
percentile (R2=0.048; p<0.001; Table S1). There was a marginal improvement in prediction 
of admission to NNU ≥48 hours from addition of the biomarkers to the maternal factors 
(AUROC; 95% CI: 0.641; 0.625-0.657 vs. 0.634; 0.618-0.650, respectively; p=0.012)   
 
Elective cesarean section for suspected fetal compromise 
 
In the 72 cases of elective cesarean section for suspected fetal compromise, the UtA-PI was 
>95th percentile in 12 (16.7%), sFLT-1 was >95th percentile in 12 (16.7%), PLGF was <5th 
percentile in 17 (23.6%) and birthweight was <10th percentile in 58 (80.6%). 
 
Performance of screening in pregnancies with SGA and non-SGA neonates 
 
The predictive performance of UtA-PI >95th percentile, sFLT-1 >95th percentile and PLGF 





The incidence of stillbirth was 0.30% (6/2,034) in babies with birthweight <10th percentile and 
0.17% (29/17,175) in those with birthweight ≥10th percentile (p=207). Consequently, 82.9% 
(29/35) of stillbirths occurred in non-SGA babies.  
 
The UtA-PI was >95th percentile in 8.6% (3/35) pregnancies with stillbirth and in 5.0% 
(958/19,174) of those with livebirth. The PLGF was <5th percentile in 8.6% (3/35) 
pregnancies with stillbirth and in 5.0% (957/19,174) of those with livebirth. The sFLT-1 was 
>95th percentile in 11.4% (4/35) pregnancies with stillbirth and in 5.0% (956/19,174) of those 
with livebirth. 
 
The relative risk for stillbirth in the group with UtA-PI >95th percentile was 1.71 in the SGA 
neonates and 1.63 in the non-SGA neonates (Table 2). The relative risk for stillbirth in the 
group with sFLT-1 >95th percentile was 1.66 in the SGA neonates and 2.56 in the non-SGA 
neonates (Table 3). The relative risk for stillbirth in the group with PLGF <5th percentile was 
1.23 in the SGA neonates and 1.81 in the non-SGA neonates (Table 4).  
 
Cesarean section for presumed fetal compromise 
 
The incidence of cesarean section for presumed fetal compromise in labor in the livebirths 
was 10.9% (183/1,686) in babies with birthweight <10th percentile and 6.1% (824/13,491) in 
those with birthweight ≥10th percentile (p<0.001). Consequently, 81.8% (824/1,007) of 
cesarean sections for presumed fetal compromise occurred in non-SGA babies.  
 
The UtA-PI was >95th percentile in 6.7% (67/1,007) pregnancies delivered by cesarean 
section for presumed fetal compromise and in 4.7% (664/14,170) of those with vaginal 
delivery. The PLGF was <5th percentile in 6.6% (66/1,007) pregnancies delivered by 
cesarean section for presumed fetal compromise and in 4.9% (697/14,170) of those with 
vaginal delivery. The sFLT-1 was >95th percentile in 7.7% (78/1,007) pregnancies delivered 
by cesarean section for presumed fetal compromise and in 4.7% (661/14,170) of those with 
vaginal delivery. 
 
The relative risk for delivery by cesarean section for presumed fetal compromise in the group 
with UtA-PI >95th percentile was 1.33 in the SGA neonates and 1.29 in the non-SGA 
neonates (Table 2). The relative risk for delivery by cesarean section for presumed fetal 
compromise in the group with sFLT-1 >95th percentile was 1.33 in the SGA neonates and 
1.61 in the non-SGA neonates (Table 3). The relative risk for delivery by cesarean section 
for presumed fetal compromise in the group with PLGF <5th percentile was 1.23 in the SGA 
neonates and 1.13 in the non-SGA neonates (Table 4).  
 
Neonatal death or hypoxic ischemic encephalopathy 
 
The incidence of neonatal death or hypoxic ischemic encephalopathy was 0.10% (3/2,034) 
in babies with birthweight <10th percentile and 0.17% (29/17,175) in those with birthweight 
≥10th percentile (p=0.556). Consequently, 90.6% (29/32) of cases of neonatal death or 
hypoxic ischemic encephalopathy occurred in non-SGA babies.  
 
The UtA-PI was >95th percentile in 9.4% (3/32) cases of neonatal death or hypoxic ischemic 
encephalopathy and in 5.0% (958/19,177) of those without this adverse outcome. The PLGF 
was <5th percentile in 3.1% (1/32) cases of neonatal death or hypoxic ischemic 
encephalopathy and in 5.0% (959/19,177) of those without this adverse outcome. The sFLT-
1 was >95th percentile in 9.4% (3/32) cases of neonatal death or hypoxic ischemic 
encephalopathy and in 5.0% (957/19,177) of those without this adverse outcome. 
 
The relative risk for neonatal death or hypoxic ischemic encephalopathy in the group with 
UtA-PI >95th percentile was 1.22 in the SGA neonates and 2.53 in the non-SGA neonates 
(Table 2). The relative risk for neonatal death or hypoxic ischemic encephalopathy in the 
group with sFLT-1 >95th percentile was 4.14 in the SGA neonates and 1.64 in the non-SGA 
neonates (Table 3). The relative risk for neonatal death or hypoxic ischemic encephalopathy 
in the group with PLGF <5th percentile was 2.04 in the SGA neonates and 0.87 in the non-
SGA neonates (Table 4).  
 
Neonatal unit admission for ≥48 hours 
 
The incidence of NNU admission for ≥48 hours was 9.5% (192/2,028) in babies with 
birthweight <10th percentile and 6.6% (1,131/17,145) in those with birthweight ≥10th 
percentile (p<0.001). Consequently, 85.5% (1,131/1,323) of cases of NNU admission for ≥48 
hours occurred in non-SGA babies.  
 
The UtA-PI was >95th percentile in 7.0% (92/1,323) cases of NNU admission for ≥48 hours 
and in 4.9% (866/17,851) of those without this adverse outcome. The PLGF was <5th 
percentile in 8.3% (110/1,323) cases of NNU admission for ≥48 hours and in 4.7% 
(847/17,851) of those without this adverse outcome. The sFLT-1 was >95th percentile in 
9.3% (123/1,323) cases of NNU admission for ≥48 hours and in 4.7% (833/17,851) of those 
without this adverse outcome. 
 
The relative risk for NNU admission for ≥48 hours in the group with UtA-PI >95th percentile 
was 1.28 in the SGA neonates and 1.36 in the non-SGA neonates (Table 2). The relative 
risk for NNU admission for ≥48 hours in the group with sFLT-1 >95th percentile was 2.32 in 
the SGA neonates and 1.72 in the non-SGA neonates (Table 3). The relative risk for NNU 
admission for ≥48 hours in the group with PLGF <5th percentile was 1.62 in the SGA 




Main findings of the study 
 
The findings of this study of routine assessment of singleton pregnancies at 35-37 weeks’ 
gestation demonstrate the following. First, 83% of stillbirths, 82% of cesarean sections for 
presumed fetal compromise in labor, 91% of cases of neonatal death or hypoxic ischemic 
encephalopathy and 86% of NNU admissions for ≥48 hours occurred in pregnancies with 
non-SGA babies. Second, UtA-PI >95th percentile, sFLT-1 >95th percentile and PLGF <5th 
percentile were associated with increased risk of of cesarean section for presumed fetal 
compromise in labor and NNU admission for ≥48 hours; the number of stillbirths and cases 
of neonatal death or hypoxic ischemic encephalopathy was too small to demonstrate 
significance in the observed differences from cases without these adverse outcomes. Third, 
multivariable regression analysis demonstrated that in prediction of cesarean section for 
presumed fetal compromise in labor there was no significant contribution from biomarkers; 
the prediction of NNU admission for ≥48 hours by maternal demographic characteristics and 
medical history was only marginally improved by the addition of UtA-PI, sFLT-1 or PLGF. 
Fourth, for each biomarker the DR of adverse outcomes was higher in SGA than in non-SGA 
babies, but such increase was accompanied by an increase in FPR. Fifth, the relative risk of 
UtA-PI >95th, sFLT-1 >95th and PLGF <5th percentiles for most adverse outcomes was <2.5 
in both SGA and non-SGA neonates. 
 
If it was to be assumed that the adverse outcomes we have investigated are the 
consequence of impaired placentation and that high UtA-PI and sFLT-1 and low PLGF are 
good markers of such impairment, it should be anticipated that these biomarkers would be 
good predictors of adverse outcome. However, the observed low performance of these 
biomarkers in the prediction of adverse perinatal outcomes suggests that first, they provide 
poor assessment of placentation or second, most cases of stillbirth at term are not 
associated with impaired placentation and the contribution of maternal and pregnancy 
characteristics as well as events in labor play a much greater role than impaired placentation 
in the development of fetal compromise in labor or adverse neonatal outcome. 
 
Comparison with findings from previous studies 
 
The results of this study are consistent with those of the only two previous screening studies 
in unselected populations that examined biomarkers of impaired placentation in 8,268 
pregnancies at 30-34 weeks’ gestation and 3,953 at 35-37 weeks, respectively, for prediction 
of adverse perinatal outcome; in both studies these markers were useful in the prediction of 
PE and birth of SGA neonates, but not of adverse events in labor or after birth.16,21 
 
Our results are also consistent with those of a prospective study of 438 low-risk pregnancies 
in which serial measurements of serum PLGF were carried out from 36 weeks’ gestation 
until delivery; the study found that low PLGF levels were associated with low birth weight 
and adverse intrapartum and neonatal outcome, but the predictive performance of low PLGF 
was poor with DR of 10-11% at FPR of 10%.22 In contrast, a prospective study in 3,747 
singleton pregnancies in nulliparous women reported that  elevated sFLT1/PlGF ratio (>85th 
percentile) at 36 weeks’ gestation in combination with EFW <10th percentile predicted 38% of 
adverse perinatal outcomes, at screen positive rate of 3%.23 However, adverse outcome was 
defined as birth of a SGA neonate associated with PE or perinatal morbidity or mortality, and 
such definition would apply to a very small proportion of all cases of stillbirth, cesarean 
section for presumed fetal compromise in labor, neonatal death or hypoxic ischemic 
encephalopathy or NNU admission for ≥48 hours. In a previous report of the same study 
population, the authors reported that SGA neonates contributed only 18% of neonatal 
morbidity and 15% of severe adverse perinatal outcome found in the total population,24 
which is consistent with our findings. 
 
Implications for clinical practice 
 
An integrated clinical assessment at 35-37 weeks’ gestation, which includes fetal biometry 
and measurement of biomarkers, identifies a high proportion of pregnancies that 
subsequently develop PE and those delivering SGA neonates.1-6 Contrary to the expectation 
that the same biomarkers would be useful in predicting adverse perinatal outcome, this did 
not prove to be the case.  
 
Strengths and limitations of the study 
 
The strengths of our study are first, examination of a large number of pregnancies attending 
for routine assessment of fetal growth and wellbeing at a prespecified gestational-age range 
at the end of the third trimester of pregnancy, second, measurement of UtA-PI by 
appropriately-trained doctors, third, measurement of sFLT-1 and PLGF by automated 
machines  that provide reproducible results, fourth, expression of the values of the 
biomarkers as MoMs after adjustment for maternal factors and reagents used that affect the 
measurements, and fifth, use of a wide range of well accepted indicators for adverse 
perinatal outcome.  
 
The main limitation of this and most previous studies investigating the biomarkers of 
impaired placentation in the prediction of adverse pregnancy outcome is that the results of 
the ultrasound scan were made available to the attending obstetricians who would have 
taken specific actions of further monitoring and planned delivery of the cases with suspected 
SGA and fetal compromise. In our study 72 such pregnancies had elective delivery by 
cesarean section; had this not been carried out it is possible that some of the cases would 
have resulted in stillbirth, cesarean section for fetal compromise in labor, birth asphyxia and 
NNU admission. Consequently, the performance of screening by UtA-PI, sFLT-1 and PLGF 
for adverse perinatal outcome in SGA fetuses would have been negatively biased. However, 
the number of these cases was very small and it is therefore unlikely that they would have 




In pregnancies undergoing routine antenatal assessment at 35 - 37 weeks’ gestation 
measurements of UtA-PI, sFLT-1 or PLGF, which has been previously found to be useful in 
prediction of PE and birth of SGA neonates, provide poor prediction of stillbirth, cesarean 
section for presumed fetal compromise in labor, NNU admission for ≥48 hours, neonatal 
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Table 1. Maternal and pregnancy characteristics in pregnancies with livebirths and stillbirths. 
 
Maternal and pregnancy 
characteristic 

















Maternal age (years) 32.1 (38.0-35.7) 31.9 (28.7-34.9) 31.8 (27.6-35.3) 31.7 (27.7-35.3) 32.1 (28.0-35.7) 31.3 (27.7-34.7) 32.2 (28.1-35.7) 30.8 (26.7-34.8)** 
Maternal weight (kg) 79.0 (71.0-89.8) 83.5 (73.5-90.3) 78.0 (70.0-88.7) 81.0 (72.0-92.0)** 79.0 (71.0-89.8) 82.7 (72.1-95.3) 79.0 (70.7-89.3) 82.0 (73.0-94.0)** 
Maternal height (cm) 165 (161-169) 165 (161-170) 165 (161-170) 163 (159-168)** 165 (161-169) 165 (159-172) 165 (161-169) 164 (160-169)* 
Maternal body mass (kg/m2) 29.0 (26.1-32.8) 29.9 (27.6-34.0) 28.6 (25.9-32.2) 30.6 (27.0-34.0)** 29.0 (26.1-32.8) 29.6 (26.4-34.5) 29.0 (26.1-32.6) 30.3 (27.1-34.6**) 
Cigarette smoker 1,319 (6.9) 5 (14.3) 1,019 (7.2) 82 (8.1) 1,323 (6.9) 1 (3.1) 1,208 (6.8) 111 (8.4)** 
Racial origin         
     White 15,022 (78.3) 23 (65.7) 11,180 (78.9) 714 (70.9)** 15,022 (78.3) 23 (71.9) 13,940 (78.1) 1,082 (81.8)** 
     Black 2,358 (12.3) 8 (22.9) 1,669 (11.8) 186 (18.5)** 2,359 (12.3) 7 (21.9)* 2,228(12.5) 130 (9.8)** 
     South Asian 826 (4.3) 1 (2.9) 604 (4.3) 49 (4.9) 825 (4.3) 2 (6.3) 754 (4.2) 72 (5.4)* 
     East Asian 400 (2.1) 1 (2.9) 304 (2.1) 17 (1.7) 401 (2.1) 0 387 (2.2) 13 (1.0)* 
     Mixed 568 (3.0) 2 (5.7) 413 (2.9) 41 (4.1)* 570 (3.0) 0 542 (3.0) 26 (2.0)* 
Conception         
     Natural 18,389 (95.9) 35 (100.0) 13,722 (96.8) 954 (94.7) 18,392 (95.9) 32 (100.0) 17,128 (95.9) 1,261 (95.3) 
     Ovulation induction drugs 110 (0.6) 0 78 (0.6) 6 (0.6) 110 (0.6) 0 98 (0.5) 12 (0.9)** 
     In vitro fertilization 675 (3.5) 0 370 (2.6) 47 (4.7)** 675 (3.5) 0 625 (3.5) 50 (3.8) 
Obstetric history         
     Nulliparous 8.997 (46.9) 13 (37.1) 6,439 (45.4) 739 (73.4)** 8,986 (46.9) 24 (75.0) 8,215 (46.0) 782 (59.1) 
     Parous, previous SGA 1,209 (6.3) 5 (14.3) 916 (6.5) 46 (4.6)* 1,214 (6.3) 0 1,154 (6.5) 55 (4.2)** 
     Parous, no previous SGA 8,968 (46.8) 17 (48.6) 6,815 (48.1) 222 (22.0)** 8,977 (46.8) 8 (25.0)* 8,482 (47.5) 486 (36.7)** 
Medical disorders         
     Chronic hypertension 209 (1.1) 0 107 (0.8) 25 (2.5)** 209 (1.1) 0 188 (1.1) 21 (1.6) 
     Diabetes mellitus 197 (1.0) 0 96 (0.7) 18 (1.8)** 197 (1.0) 0 175 (1.0) 22 (1.7)* 
Pregnancy complications         
     Preeclampsia 413 (2.2) 1 (2.9) 234 (1.7) 64 (6.4)** 411 (2.1) 3 (9.4)* 348 (1.9) 65 (4.9)** 
     Gestational diabetes 766 (4.0) 1 (2.9) 462 (3.3) 48 (4.8)* 767 (4.0) 0 697 (3.9) 69 (5.2)* 
     Obstetric cholestasis 151 (0.8) 1 (2.9) 108 (0.8) 10 (1.0) 151 (0.8) 1 (3.1) 121 (0.7) 30 (2.3)** 
Biomarkers of impaired placentation         
     Uterine artery PI (MoM) 0.96 (0.82-1.14) 1.10 (0.87-1.18) 0.96 (0.82-1.14) 0.94 (0.79-1.15) 0.96 (0.82-1.14) 0.97 (0.74-1.12) 0.96 (0.82-1.13) 0.96 (0.81-1.17) 
     Uterine artery PI >95th percentile 958 (5.0) 3 (8.6)* 664 (4.7) 67 (6.7)** 958 (5.0) 3 (9.4) 866 (4.9) 92 (7.0)** 
 
Data are given as median (interquartile range) for continuous variables and n(%) for categorical variables.  
CS = caesarean section; FC = presumed fetal compromise; NND = neonatal death; HIE = hypoxic ischemic encephalopathy; NNU = neonatal unit; SGA = 
small for gestational age with birthweight <10th percentile; PE = preeclampsia; PI = pulsatility index; MoM = multiple of the median 
 
Significance value * p<0.05; ** p<0.01 
 
  
     Serum PLGF (MoM) 0.96 (0.53-1.73) 0.83 (0.39-1.22) 0.95 (0.53-1.72) 0.92 (0.49-1.73) 0.96 (0.53-1.73) 1.24 (0.58-2.18) 0.97 (0.54-1.73) 0.83 (0.45-1.61)** 
     Serum PLGF <5th percentile 957 (5.0) 3 (8.6) 697 (4.9) 66 (6.6)* 959 (5.0) 1 (3.1) 847 (4.7) 110 (8.3)** 
     Serum sFLT-1 (MoM) 0.96 (0.70-1.39) 1.37 (0.87-2.43)** 0.96 (0.70-1.38) 1.02 (0.72-1.50)* 0.96 (0.70-1.39) 1.04 (0.77-1.49) 0.96 (0.70-1.38) 1.04 (0.72-1.60)** 
     Serum sFLT-1 >95th percentile 956 (5.0) 4 (11.4)* 661 (4.7) 78 (7.7)** 957 (5.0) 3 (9.4) 833 (4.7) 123 (9.3)** 
Estimated weight <10th percentile 1,488 (7.8) 4 (11.4) 1,165 (8.2) 97 (9.6) 1,491 (7.8) 1 (3.1) 1,367 (7.7) 121 (9.1) 
GA at delivery in weeks 40.0 (39.1-40.9) 39.7 (38.7-41.3) 40.1 (39.3-40.9) 40.4 (39.4-41.3)* 40.0 (39.1-40.9) 40.1 (39.1-40.6) 40.0 (39.1-40.9) 39.9 (38.4-40.9)** 
Birth weight (g) 3440 (3130-3755) 3250 (2920-3460) 3435 (3130-3740) 3400 (3050-3750) 3440 (3130-3755) 3596 (3282-3790) 3440 (3135-3750) 3410 (3030-3780)* 
Birth weight <10th percentile 2,028 (10.6) 6 (17.1)** 1,503 (10.6) 183 (18.2)** 2,031 (10.6) 3 (9.4) 1,836 (10.3) 192 (14.5)** 
Table S1. Multivariable logistic regression analysis in prediction of adverse perinatal outcomes from maternal and pregnancy characteristics 
and biomarkers of impaired placentation. 
 
Maternal and pregnancy 
characteristic 
Stillbirth CS for fetal compromise NND or HIE 2/3 NNU admission 
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Maternal age - 30 (years)   1.04 (1.02-1.05) <0.001   0.97 (0.96-0.98) <0.001 
Maternal BMI - 30  (kg/m2) 1.08 (1.02-1.31) 0.007 1.07 (1.06-1.08) <0.001   1.06 (1.05-1.07) <0.001 
Cigarette smoker   1.56 (1.22-2.00) <0.001     
Racial origin         
     White         
     Black   1.85 (1.55-2.21) <0.001   0.70 (0.58-0.85) <0.001 
     South Asian       1.30 (1.01-1.68) <0.001 
     East Asian         
     Mixed   1.59 (1.13-2.23) 0.007     
Conception         
     Natural         
     Ovulation induction drugs         
     In vitro fertilization         
Obstetric history         
     Nulliparous         
     Parous, previous SGA  2.64 (1.02-6.84) 0.045 0.36 (0.26-0.50) <0.001   0.53 (0.40-0.70) <0.001 
     Parous, no previous SGA    0.23 (0.20-0.27) <0.001 0.40 (0.18-0.89) 0.024 0.61 (0.54-0.69) <0.001 
Medical disorders         
     Chronic hypertension   2.13 (1.33-3.42) 0.002     
     Diabetes mellitus   2.72 (1.60-4.61) <0.001     
Pregnancy complications         
     Preeclampsia   2.62 (1.94-3.53) <0.001 4.05 (1.22-13.43) 0.022 1.60 (1.19-2.14) 0.002 
     Gestational diabetes         
     Obstetric cholestasis       3.06 (2.02-4.64) <0.001 
Biomarkers of impaired placentation         
 
 
OR = odds ratio; CI = confidence interval; BMI = body mass index; NND = neonatal death; HIE = hypoxic ischemic encephalopathy; NNU = neonatal unit; 
SGA = small for gestational age with birthweight <10th percentile; PE = preeclampsia; PI = pulsatility index; MoM = multiple of the median. 
 
     Uterine artery PI >95th percentile         
     Serum PLGF <5th percentile       1.50 (1.20-1.89) <0.001 
     Serum sFLT-1 >95th percentile       1.55 (1.24-1.93) <0.001 
Estimated weight <10th percentile       1.25 (1.02-1.52) 0.034 
Table 2. Predictive performance of uterine artery pulsatility index >95th percentile for adverse 
perinatal outcome in small and non-small for gestational age neonates. 
 
 
Values in brackets are 95% confidence intervals 
  
Adverse outcome 
Uterine artery pulsatility index >95th percentile 
BW ≥10th percentile BW <10th percentile 
Stillbirth (n=35)   
  Detection rate 6.9 (4.3-9.3) 16.7 (11.7-21.5) 
  False positive rate 4.4 (3.0-5.9) 10.5 (6.4-14.6) 
  Relative risk 1.63 (0.39-6.83)  1.71 (0.20-14.57) 
  Positive likelihood ratio  1.59 (0.42-6.05) 1.59 (0.27-9.59) 
  Negative likelihood ratio 0.97 (0.88-1.07) 0.93 (0.65-1.33) 
Cesarean section for fetal compromise (n=1,007)   
  Detection rate 5.3 (4.2-6.4) 12.6 (10.8-14.4) 
  False positive rate 4.1 (3.0-5.1) 9.4 (7.9-10.9) 
  Relative risk 1.29 (0.96-1.62) 1.33 (0.88-1.99) 
  Positive likelihood ratio  1.30 (0.96-1.75) 1.33 (0.88-2.01) 
  Negative likelihood ratio 0.99 (0.97-1.01) 0.97 (0.91-1.02) 
Neonatal death or HIE (n=32)   
  Detection rate 10.3 (9.5-11.6) 0 
  False positive rate 4.3 (4.0-4.6) 10.5 (10.1-10.9) 
  Relative risk 2.53 (0.77-8.35) 1.22 (0.06-23.47) 
  Positive likelihood ratio  2..38 (0.81-6.97) 0 
  Negative likelihood ratio 0.94 (0.83-1.06) 1.12 (1.10-1.13) 
Neonatal unit admission for 48 hours (n=1,323)   
  Detection rate 5.8 (5.5-6.3) 13.5 (12.0-15.1) 
  False positive rate 4.2 (3.9-4.5) 10.1 (8.7-11.5) 
  Relative risk 1.36 (1.07-1.73) 1.28 (0.86-1.93) 
  Positive likelihood ratio  1.37 (1.08-1.76) 1.28 (0.86-1.90) 
  Negative likelihood ratio 0.98 (0.97-1.00) 0.97 (0.91-1.03) 
Table 3. Predictive performance of serum soluble fms-like tyrosine kinase-1 >95th percentile 
for adverse perinatal outcome in small and non-small for gestational age neonates. 
 
 
Values in brackets are 95% confidence intervals 
  
Adverse outcome 
Soluble fms-like tyrosine kinase-1 >95th percentile 
BW ≥10th percentile BW <10th percentile 
Stillbirth (n=35)   
  Detection rate 10.3 (9.3-11.3) 16.7 (15.0-18.4) 
  False positive rate 4.3 (4.0-4.6) 10.7 (9.3-12.1) 
  Relative risk 2.56 (0.78-8.44) 1.66 (0.19-14.12) 
  Positive likelihood ratio  2.40 (0.82-7.03) 1.55 (0.26-9.32) 
  Negative likelihood ratio 0.94 (0.83-1.06) 0.93 (0.65-1.34) 
Cesarean section for fetal compromise (n=1,007)   
  Detection rate 6.7 (6.3-7.1) 12.6 (11.1-14.2) 
  False positive rate 4.1 (3.8-4.4) 9.4 (8.0-10.8) 
  Relative risk 1.61 (1.24-2.0) 1.33 (0.88-1.99) 
  Positive likelihood ratio  1.63 (1.25-2.13) 1.33 (0.88-2.01) 
  Negative likelihood ratio 0.97 (0.96-0.99) 0.97 (0.91-1.02) 
Neonatal death or HIE (n=32)   
  Detection rate 6.9 (6.4-7.3) 33.3 (30.4-37.1) 
  False positive rate 4.3 (4.0-4.6) 10.7 (9.3-12.1) 
  Relative risk 1.64 (0.39-6.90) 4.14 (0.38-15.51) 
  Positive likelihood ratio  1.60 (0.42-6.11) 3.11 (0.62-15.46) 
  Negative likelihood ratio 0.97 (0.88-1.07) 0.75 (0.34-1.66) 
Neonatal unit admission for 48 hours (n=1,323)   
  Detection rate 7.2 (6.8-7.6) 21.9 (19.2-23.4) 
  False positive rate 4.1 (3.8-4.4) 9.6 (8.2-10.9) 
  Relative risk 1.72 (1.39-2.12) 2.32 (1.71-3.17) 
  Positive likelihood ratio  1.75 (1.40-2.18) 2.28 (1.69-3.09) 
  Negative likelihood ratio 0.97 (0.95-0.98) 0.86 (0.80-0.93) 
Table 4. Predictive performance of serum placental growth factor <5th percentile for adverse 
perinatal outcome in small and non-small for gestational age neonates. 
 
 





Placental growth factor <5th percentile 
BW ≥10th percentile BW <10th percentile 
Stillbirth (n=35)   
  Detection rate 6.9 (6.6-7.2) 16.7 (15.0-18.5) 
  False positive rate 3.9 (3.6-4.2) 14.0 (12.4-15.6) 
  Relative risk 1.81 (0.43-7.60) 1.23 (0.14-10.47) 
  Positive likelihood ratio  1.76 (0.46-6.71) 1.19 (0.20-7.15) 
  Negative likelihood ratio 0.97 (0.88-1.07) 0.97 (0.68-1.39) 
Cesarean section for fetal compromise (n=1,007)   
  Detection rate 4.5 (4.2-4.8) 15.8 (13.7-17.1) 
  False positive rate 4.0 (3.7-4.3) 13.0 (11.4-14.7) 
  Relative risk 1.13 (0.83-1.55) 1.23 (0.85-1.78) 
  Positive likelihood ratio  1.13 (0.82-1.57) 1.22 (0.85-1.75) 
  Negative likelihood ratio 0.99 (0.98-1.01) 0.97 (0.91-1.03) 
Neonatal death or HIE (n=32)   
  Detection rate 3.4 (2.9-3.8) 0 
  False positive rate 3.9 (3.6-4.2) 14.0 (12.4-15.6) 
  Relative risk 0.87 (0.12-6.41) 2.04 (0.08-49.94) 
  Positive likelihood ratio  0.88 (0.13-6.03) 0 
  Negative likelihood ratio 1.01 (0.94-1.08) 1.16 (1.14-1.18) 
Neonatal unit admission for 48 hours (n=1,323)   
  Detection rate 6.2 (5.9-6.5) 20.8 (18.9-22.7) 
  False positive rate 3.8 (3.5-4.1) 13.3 (11.7-14.9) 
  Relative risk 1.61 (1.28-2.03) 1.62 (1.17-2.24) 
  Positive likelihood ratio  1.64 (1.29-2.09) 1.57 (1.16-2.11) 
  Negative likelihood ratio 0.97 (0.96-0.99) 0.91 (0.85-0.98) 
